Rapid fluoroquinolone resistance detection in *Pseudomonas aeruginosa* using mismatch amplification mutation assay-based real-time PCR

Danielle E. Madden[1,2,3], Kate L. McCarthy[4,5], Scott C. Bell[6,7,8], Olusola Olagoke[1,2,3], Timothy Baird[2,9], Jane Neill[9], Kay A. Ramsay[8], Timothy J. Kidd[10,11], Adam G. Stewart[5,12], Shradha Subedi[3,12], Keat Choong[3,12], Tamieka A. Fraser[1,2], Derek S. Sarovich[1,2,3*], and Erin P. Price[1,2,3*]

[1]GeneCology Research Centre, University of the Sunshine Coast, Sippy Downs, Queensland, Australia
[2]Sunshine Coast Health Institute, Birtinya, Queensland, Australia
[3]Infection Research Network Sunshine Coast, Birtinya, Queensland, Australia
[4]Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
[5]University of Queensland Centre for Clinical Research, Herston, Queensland, Australia
[6]Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, Queensland, Australia
[7]Translational Research Institute, Woolloongabba, Queensland, Australia
[8]Child Health Research Centre, The University of Queensland, Centre for Children's Health Research, South Brisbane, QLD, Australia
[9]Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia
[10]School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia
[11]Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
[12]Infectious Diseases Unit, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

Keywords: Antibiotic, AMR, fluoroquinolone, ciprofloxacin, *Pseudomonas aeruginosa*, real-time PCR, SYBR-MAMA

Running title: Rapid FQ resistance detection in *P. aeruginosa*

*Authors contributed equally

Corresponding author: Erin Price, eprice@usc.edu.au Ph: +61 7 5456 5568

27 **Abstract**

28 **Background:** Antimicrobial resistance (AMR) is an ever-increasing global health concern. One crucial
29 facet in tackling the AMR epidemic is earlier and more accurate AMR diagnosis, particularly in the
30 dangerous and highly multi-drug resistant ESKAPE pathogen, *Pseudomonas aeruginosa*.

31 **Objectives:** We aimed to develop two SYBR Green-based mismatch amplification mutation assays
32 (SYBR-MAMAs) targeting GyrA T83I (*gyrA*248), and GyrA D87N, D87Y, and D87H (*gyrA*259).
33 Together, these variants cause the majority of fluoroquinolone (FQ) AMR in *P. aeruginosa*.

34 **Methods:** Following assay validation, the *gyrA*248 and *gyrA*259 SYBR-MAMAs were tested on 84
35 clinical *P. aeruginosa* isolates from Queensland, Australia, 45 of which demonstrated
36 intermediate/full ciprofloxacin resistance according to antimicrobial susceptibility testing.

37 **Results:** Our two SYBR-MAMAs correctly predicted an AMR phenotype in the majority (84%) of
38 isolates with intermediate/full FQ resistance. Importantly, all FQ-sensitive strains were predicted to
39 have a sensitive phenotype. Whole-genome sequencing confirmed 100% concordance with SYBR-
40 MAMA genotypes.

41 **Conclusions:** Our GyrA SYBR-MAMAs provide a rapid and cost-effective method for same-day
42 identification of FQ AMR in *P. aeruginosa*. An additional SYBR-MAMA targeting the GyrB
43 S466Y/S466F variants would increase FQ AMR prediction to 91%. Clinical implementation of our
44 assays will permit more timely treatment alterations in cases where decreased FQ susceptibility is
45 identified, leading to improved patient outcomes and antimicrobial stewardship.

46 **Background**

47 The ESKAPE pathogen, *P. aeruginosa*, has a remarkable capacity to develop AMR towards all
48 clinically-relevant antibiotic classes (1). This bacterium can cause life-threatening infections,
49 particularly in people with wounds, cancer, or chronic respiratory diseases such as cystic fibrosis (CF)
50 or chronic obstructive pulmonary disease (COPD) (2).

51 Rapid, affordable, accessible, and accurate AMR diagnosis is crucial in the battle against ESKAPE
52 pathogens (1). However, few diagnostic tests exist (3) for rapidly and inexpensively characterising
53 AMR-conferring single-nucleotide polymorphisms (SNPs) in *P. aeruginosa*, a striking knowledge gap
54 given that SNPs confer AMR towards anti-pseudomonal drugs such as fluoroquinolones (FQs) (4).

55 FQs (predominantly ciprofloxacin [CIP]) have proven clinically useful for treating *P. aeruginosa*
56 infections (5). Yet, upon exposure, *P. aeruginosa* often develops FQ resistance (FQr). Codon-altering
57 mutations within the GyrA quinolone-resistance-determining region (QRDR) can confer an
58 intermediate (CIPi) or fully resistant (CIPr) CIP phenotype (6, 7); in contrast, *gyrB*, *parC*, *parE* and
59 *nfxB* typically require ≥2 mutations to impart CIPi/CIPr (8).

60 Due to the single-step nature of QRDR mutations in conferring CIPi/CIPr, and their prevalence in
61 clinical isolates (9), we targeted the two most common QRDR SNPs, *gyrA*248 (4) and *gyrA*259 (10),
62 for assay development. We chose SYBR Green-based mismatch amplification mutation assay (SYBR-
63 MAMA), an inexpensive (~AUD$1-2/assay when run in duplicate), simple, rapid (~1h turnaround
64 time) and scalable method (11-15) that exploits the differential efficiency of allele-specific
65 amplification for SNP interrogation; this efficiency disparity can be observed in real-time by
66 measuring the difference in cycles-to-threshold (ΔC_T) (12, 14, 15).

67 **Methods**

68 Eighty-four *P. aeruginosa* isolates from Southeast Queensland, Australia, were examined: 42 from
69 sputum derived from adults with CF and chronic *P. aeruginosa* infection admitted to The Prince
70 Charles Hospital between 2017 and 2019 (16); 35 bloodstream isolates retrieved from adults
71 admitted to several public and private hospitals in Brisbane between 2008 and 2011 (17), three from
72 COPD sputum, collected during in-home community nurse visits in the Sunshine Coast region (16);
73 one from an adult with non-CF bronchiectasis collected in 2017, and one from an adult with urinary
74 tract infection collected in 2018, both during admission to the Sunshine Coast University Hospital
75 (Table 1). One ulcer and one ear infection isolate, both from Brisbane, were obtained from the 1,000
76 International *P. aeruginosa* Consortium collection (18). Ethics approvals were obtained as previously
77 described (16, 17, 19).

78 Strains were isolated using MacConkey agar (Oxoid, VIC, Australia) incubated at 37°C for 24h and
79 confirmed as *P. aeruginosa* by *ecfX* real-time PCR (20). Susceptibility towards CIP [5µg], levofloxacin
80 (LEV; 5 µg), moxifloxacin (MFX; 5 µg), and ofloxacin (OFX; 5 µg) was determined by disc diffusion
81 (Edwards Group, QLD, Australia) using CLSI M100S-Ed27:2017 guidelines (Table 2).

82 Isolates were DNA-extracted using the DNeasy kit (Qiagen, Chadstone Centre, VIC, Australia),
83 followed by Illumina paired-end whole-genome sequencing (WGS) (19). Quality-filtered reads (21)
84 were assembled with MGAP v1.1 (https://github.com/dsarov/MGAP---Microbial-Genome-
85 Assembler-Pipeline) or SPAdes (22). AMR prediction was undertaken using a *P. aeruginosa*-specific
86 ARDaP (23) database. Assemblies were deposited into the PubMLST database
87 (https://pubmlst.org/organisms/pseudomonas-aeruginosa). Illumina data are available via
88 BioProject PRJNA761496. We also tested rapid DNA extraction of 10 representative strains using the
89 5% chelex-100 rapid heat soak method (24), followed by a 1:10 dilution in molecular-grade H_2O prior
90 to PCR.

91 SYBR-MAMA primers were assessed *in silico* for dimer formation and specificity as described
92 previously (25). For the *gyrA*248 SYBR-MAMA, gyrA248_T_AMR amplifies the CIPi/CIPr-conferring
93 T83I allele, whereas gyrA248_C_WT amplifies the wild-type allele (Table 3). For the *gyrA*259 SYBR-
94 MAMA, gyrA259_D_AMR amplifies mutant alleles at position 259 (D87N, D87Y, D87H), all of which
95 confer CIPi/CIPr (4, 8), whereas gyrA259_G_WT amplifies the wild-type allele (10). PCRs consisted of
96 1× SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, NSW, Australia), 0.2µM primers, 1µL
97 template, and PCR-grade H_2O, to 5µL. Thermocycling comprised 95°C for 2min, followed by 40 cycles
98 of 95°C for 5s and 60°C for 5sec. Strains used to validate *gyrA* 248 and 259 alleles are listed in Table
99 2.

100 **Results**

101 SYBR-MAMAs were screened across the 85 genome-sequenced *P. aeruginosa* isolates, comprising 40
102 CIP-sensitive (including PAO1), 29 CIPi, and 16 CIPr strains (Table 1). Of these, only one,
103 SCHI0050.S.1, was derived from a participant receiving FQ (CIP) treatment, and this isolate was CIP-
104 sensitive (Table 1). Unexpectedly, none of the 45 CIPi/CIPr strains were from participants known to
105 be receiving contemporaneous FQ antibiotics (Table 1), although we were unable to investigate
106 historical FQ exposure due to ethical limitations on participant data collection. It is therefore
107 possible that some of our participants have previously received FQ antibiotics in the weeks or
108 months prior to our sample collection. Alternatively, given that most of our participants were
109 hospitalised, another possibility is that the CIPi/CIPr strains were nosocomially acquired, either from
110 other admitted patients who had or were being treated with FQs, or from the hospital environment.

111 The *gyrA*248 SYBR-MAMA robustly discriminated GyrA T83I from wild-type strains, with matched
112 alleles consistently amplifying earlier than mismatched counterparts (T83I ΔC_T=4.0±0.03 vs. wild-
113 type ΔC_T=7.6±0.1 [Figures 1A and 1B]). Four tested GyrA T83I strains also demonstrated
114 intermediate or full resistance towards LEV, MFX, and OFX (Table 2), confirming the importance of
115 this variant in broader FQr. T83I is considered the most common GyrA variant in CIPi/CIPr strains (4,
116 9, 26); for example, two Japanese studies reported 82% (60/73) (27) and 75% (112/150) (28) T83I
117 prevalence among CIPi/CIPr isolates, and a Vietnamese study reported 54% (76/141) prevalence (9).
118 In our dataset, T83I was detected in 29% (13/45) CIPi/CIPr strains and 0% (0/40) CIP-sensitive strains
119 (Table 1), suggesting that T83I is an important, but not dominant, cause of CIPi/CIPr in Australian
120 isolates, although testing across a broader isolate collection is required to confirm this observation.

121 Like *gyrA*248, there was clear discrimination between AMR and wild-type genotypes for the *gyrA*259
122 SYBR-MAMA, with AMR alleles amplifying earlier in AMR-encoding strains (D87Y ΔC_T=14.7 [Figure
123 2A]; D87N ΔC_T=9.6±0.04 [Figure 2B]; D87H ΔC_T=13.5±0.2 [Figure 2C]), and vice versa for wild-type
124 strains (ΔC_T=10.8; Figure 2D). *gyrA*259 AMR was detected in 56% (25/45) CIPi/CIPr and 0% (0/40)

125 CIP-sensitive strains. The degenerate nature of the *gyrA*259 AMR primer has the advantage of
126 enabling all four nucleotide variants to be detected using just two reactions; it does not require each
127 variant to be tested individually. We therefore used WGS to differentiate each of the *gyrA*259 AMR
128 variants to determine their prevalence. D87H was most common according to WGS, accounting for
129 88% (22/25) *gyrA*259 AMR strains (Table 1). In no instance did we observe a strain encoding both
130 *gyrA*248 and *gyrA*259 AMR variants.

131 Like T83I, seven tested strains encoding D87Y, D87N and D87H all exhibited intermediate or full LEV,
132 MFX, and OFX resistance (Table 2). The *gyrA* mutations had a larger impact on MFX and OFX (causing
133 AMR) compared with CIP and LEV (causing intermediate resistance) (Table 2). This observation
134 supports the hypothesis that additional mutation/s are sometimes required to confer AMR towards
135 CIP and LEV (10).

136 We tested our two SYBR-MAMAs against rapid chelex-extracted heat soak DNA. In all instances,
137 isolates yielded excellent, early amplification, and genotyped as expected. Although not tested in
138 this study, further time savings could be made by performing SYBR-MAMAs using colony PCR (29);
139 however, in our experience, this approach requires a high degree of skill due to the inhibitory nature
140 of total cellular extracts in PCR, and typically results in a proportion of PCR failures, even with skilled
141 operators. This issue is particularly acute when using low (e.g. 5 µL) reaction volumes, as was used in
142 our study to minimise costs. Therefore, we recommend that chelex extractions followed by 1:10
143 dilution be performed where rapid DNA extraction is desired to ensure 100% amplification success.

144 Of the seven CIPi/CIPr strains that did not encode *gyrA*248 or *gyrA*259 AMR variants, three had GyrB
145 Ser466Phe or Ser466Tyr missense mutations with or without other FQr-conferring mutations (ParE
146 Ala473Val, MexR Gln25Stop), whereas four had no known FQr determinants (Table 1). A possible
147 explanation for these latter strains is phenotype misclassification as 3/4 strains sat on the
148 CIPi/sensitivity breakpoint. Although not performed in this study, determining the minimum

149 inhibitory concentration of these strains using Etests or broth microdilution may help resolve these
150 borderline phenotypes.

151 **Conclusions**

152 Our two *gyrA*248 and *gyrA*259 SYBR-MAMAs detected FQ non-susceptibility in 84% Australian
153 CIPi/CIPr strains. Importantly, all FQ-sensitive strains yielded wild-type genotypes for both assays,
154 demonstrating 100% specificity. Our two *gyrA* SYBR-MAMAs thus provide a same-day, inexpensive,
155 simple, and accurate tool for detecting the two most prevalent causes of FQ non-susceptibility in *P.*
156 *aeruginosa*. An additional SYBR-MAMA targeting GyrB Ser466Phe and Ser466Tyr would increase
157 detection of FQ non-susceptibility to 91% without loss of specificity. Conversion of our assays to
158 single-tube Melt-MAMA format (11) would further decrease assay costs and PCR setup time.

Acknowledgements

We thank Patrick Harris at UQ Centre for Clinical Research for helpful discussions.

Funding

This work was supported by Advance Queensland (awards AQIRF0362018 and AQRF13016-17RD2), an Australian Government Research Training Program Scholarship, the Wishlist Sunshine Coast Health Foundation (award 2019-14), and the National Health and Medical Research Council (award 455919).

Transparency declaration

The authors declare no competing interests. The funders had no role in study design, data acquisition, analysis, interpretation, writing or submission of the manuscript.

171 **Tables**

172 **Table 1. *Pseudomonas aeruginosa* isolates used in this study, and their DNA gyrase A (GyrA) SYBR-MAMA PCR genotypes, whole-genome sequencing**

173 **(WGS) results, multilocus sequence types, and treatment details**

Strain	Disease	*gyrA*248 allele (PCR)	*gyrA*259 allele (PCR)	GyrA AMR mutation (WGS)	Other CIP AMR-conferring mutations (WGS)	Sequence Type	Treatment at time of collection
CIP-resistant							
SCHI0004.S.5	CF	AMR	WT	T83I	None	ST649	Day 14 IV MEM, TOB
SCHI0008.S.3	CF	AMR	WT	T83I	None	ST649	Day 8 IV ATM, DOX
SCHI0010.S.1	CF	AMR	WT	T83I	None	ST4	Day 7 IV CAZ, TOB
SCHI0016.S.124	UTI	WT	AMR	D87N	MexR (Ile24fs; loss; upregulates MexAB efflux pump)	ST309	Unknown
SCHI0021.S.7	CF	WT	AMR	D87H	None	ST801	Day 13 IV CAZ, TOB
SCHI0025.S.15	CF	WT	AMR	D87H	None	ST801	Unknown
SCHI0027.S.1	CF	WT	AMR	D87H	None	ST801	Day 1 IV CAZ, TOB
SCHI0029.S.1	CF	WT	AMR	D87H	None	ST801	Day 1 unknown antibiotic/s
SCHI0030.S.4	CF	WT	AMR	D87H	None	ST801	None
SCHI0032.S.32	Ulcer	WT	AMR	D87N	None	ST143#	Unknown
SCHI0032.S.33	Ear infection	WT	AMR	D87Y	None	ST848^	Unknown
SCHI0033.S.2	BSI	AMR	WT	T83I	ParE (Ala473Val), NalD (Met1del; upregulates MexAB efflux pump)	ST847	Unknown

SCHI0033.S.4	BSI	AMR	WT	T83I	None	ST244	Unknown
SCHI0033.S.15	BSI	AMR	WT	T83I	ParC (Ser87Leu)	ST532	Unknown
SCHI0033.S.19	BSI	AMR	WT	T83I	ParC (Ser87Leu)	ST235	Unknown
SCHI0033.S.26	BSI	WT	WT	None	None	ST147	Unknown
CIP-intermediate							
SCHI0002.S.8	CF	WT	WT	None	GyrB (Ser466Phe)	ST4	Day 7 IV CAZ, MEM, TOB
SCHI0002.S.9	CF	WT	WT	None	None	ST683	Day 7 IV CAZ, MEM, TOB
SCHI0002.S.12	CF	WT	WT	None	None	ST683	Day 37 IV CAZ, MEM, TOB
SCHI0003.S.1	CF	AMR	WT	T83I	None	ST649	Day 4 IV ATM, MEM, TOB
SCHI0003.S.3	CF	AMR	WT	T83I	None	ST649	Day 4 IV ATM, MEM, TOB
SCHI0003.S.8	CF	WT	AMR	D87H	None	ST801	Day 4 IV ATM, MEM, TOB
SCHI0005.S.9	CF	WT	AMR	D87H	None	ST801	Day 10 IV MEM, TOB
SCHI0005.S.10	CF	WT	AMR	D87H	None	ST801	Day 10 IV MEM, TOB
SCHI0005.S.11	CF	WT	AMR	D87H	None	ST801	Day 10 IV MEM, TOB
SCHI0006.S.10	CF	WT	AMR	D87H	None	ST801	None
SCHI0008.S.2	CF	AMR	WT	T83I	None	ST649	Day 8 IV ATM, DOX
SCHI0008.S.4	CF	AMR	WT	T83I	None	ST649	Day 8 IV ATM, DOX
SCHI0013.S.12	CF	WT	WT	None	GyrB (Ser466Tyr), ParE (Ala473Val)	ST775	Day 4 FOF, MEM
SCHI0016.S.57	BE	WT	WT	None	GyrB (Ser466Phe), MexR (Gln25stop; upregulates MexAB efflux pump)	ST2601	>2 weeks MEM, GEN, CRO, FEP
SCHI0021.S.5	CF	WT	AMR	D87H	None	ST801	Day 5 IV CAZ, TOB

SCHI0021.S.6	CF	WT	AMR	D87H	None	ST801	Day 5 IV CAZ, TOB
SCHI0021.S.8	CF	WT	AMR	D87H	None	ST801	Day 13 IV CAZ, TOB
SCHI0021.S.10	CF	WT	AMR	D87H	None	ST801	Day 1 IV CAZ, TOB
SCHI0021.S.11	CF	WT	AMR	D87H	None	ST801	Day 1 IV CAZ, TOB
SCHI0021.S.12	CF	WT	AMR	D87H	None	ST801	Day 1 IV CAZ, TOB
SCHI0021.S.14	CF	WT	AMR	D87H	None	ST801	None
SCHI0025.S.9	CF	AMR	WT	T83I	None	ST649	Unknown
SCHI0027.S.2	CF	WT	AMR	D87H	None	ST801	Day 12 IV CAZ, TOB
SCHI0027.S.3	CF	WT	AMR	D87H	None	ST801	Day 9 IV CAZ, TOB
SCHI0027.S.5	CF	WT	AMR	D87H	None	ST801	None
SCHI0030.S.2	CF	WT	AMR	D87H	None	ST801	Day 6 IV ATM, TOB
SCHI0030.S.3	CF	WT	AMR	D87H	None	ST801	Day 13 IV ATM, TOB
SCHI0033.S.14	BSI	WT	WT	None	None	ST571	Unknown
SCHI0033.S.29	BSI	AMR	WT	T83I	None	ST244	Unknown
CIP-sensitive							
SCHI0005.S.8	CF	WT	WT	None	ParE (Ala473Val), AmgS (Val121Gly; upregulates MexXY efflux pump)	ST262	Day 10 IV MEM, TOB
SCHI0013.S.2	CF	WT	WT	None	GyrB (Ser466Tyr), ParE (Ala473Val)	ST775	Day 4 FOF, MEM
SCHI0020.S.4	CF	WT	WT	None	ParE (Ala473Val), NfxB (large deletion, upregulates MexCD efflux pump)	ST3828*	Day 1 IV CAZ, TOB
SCHI0020.S.5	CF	WT	WT	None	ParE (Ala473Val), NfxB (large deletion, upregulates MexCD efflux pump)	ST3828*	None

SCHI0020.S.6	CF	WT	WT	None	ParE (Ala473Val), NfxB (loss, upregulates MexCD efflux pump)	ST3828*	Day 1 IV CAZ, TOB
SCHI0027.S.4	CF	WT	WT	None	None	ST801	None
SCHI0030.S.1	CF	WT	WT	None	None	ST275	None
SCHI0030.S.5	CF	WT	WT	None	None	ST275	None
SCHI0033.S.1	BSI	WT	WT	None	None	ST3864*	Unknown
SCHI0033.S.3	BSI	WT	WT	None	None	ST3829	Unknown
SCHI0033.S.5	BSI	WT	WT	None	None	ST274	Unknown
SCHI0033.S.7	BSI	WT	WT	None	None	ST252	Unknown
SCHI0033.S.8	BSI	WT	WT	None	None	ST649	Unknown
SCHI0033.S.9	BSI	WT	WT	None	None	ST708	Unknown
SCHI0033.S.10	BSI	WT	WT	None	None	ST244	Unknown
SCHI0033.S.11	BSI	WT	WT	None	None	ST3865*	Unknown
SCHI0033.S.12	BSI	WT	WT	None	None	ST865	Unknown
SCHI0033.S.13A	BSI	WT	WT	None	None	ST395	Unknown
SCHI0033.S.13B	BSI	WT	WT	None	None	ST395	Unknown
SCHI0033.S.16	BSI	WT	WT	None	NfxB (Phe126fs; upregulates MexCD efflux pump)	ST909	Unknown
SCHI0033.S.17	BSI	WT	WT	None	None	ST274	Unknown
SCHI0033.S.18	BSI	WT	WT	None	None	ST348	Unknown
SCHI0033.S.20	BSI	WT	WT	None	None	ST274	Unknown
SCHI0033.S.23	BSI	WT	WT	None	None	ST3843*	Unknown
SCHI0033.S.24	BSI	WT	WT	None	None	ST471	Unknown
SCHI0033.S.25	BSI	WT	WT	None	None	ST815	Unknown
SCHI0033.S.27	BSI	WT	WT	None	None	ST395	Unknown

SCHI0033.S.28	BSI	WT	WT	None	None	ST3804	Unknown
SCHI0033.S.30	BSI	WT	WT	None	None	ST782	Unknown
SCHI0033.S.32	BSI	WT	WT	None	None	ST298	Unknown
SCHI0033.S.33	BSI	WT	WT	None	MexR (Arg91fs; upregulates MexAB efflux pump	ST17	Unknown
SCHI0033.S.35	BSI	WT	WT	None	None	ST348	Unknown
SCHI0033.S.36	BSI	WT	WT	None	None	ST3830*	Unknown
SCHI0033.S.37	BSI	WT	WT	None	None	ST298	Unknown
SCHI0033.S.38	BSI	WT	WT	None	None	ST235	Unknown
SCHI0033.S.39	BSI	WT	WT	None	None	ST1189	Unknown
SCHI0038.S.3	COPD	WT	WT	None	None	ST888	None
SCHI0039.S.1	COPD	WT	WT	None	None	ST3134	None
SCHI0050.S.1	COPD	WT	WT	None	ParC (Gln405Arg)	ST3323	Day 3 oral CIP
PAO1	Wound	WT	WT	None	None	ST549	Unknown

174 Abbreviations: AMR, antimicrobial-resistant; ATM, aztreonam; BE, bronchiectasis; BSI, bloodstream infection, CAZ, ceftazidime; CF, cystic fibrosis; CIP,

175 ciprofloxacin; COPD, chronic obstructive pulmonary disease; CRO, ceftriaxone; DOX, doxycycline; FEP, cefepime; FOF, fosfomycin; GEN, gentamicin; IV,

176 intravenous; MEM, meropenem; SYBR-MAMA, SYBR Green-based mismatch amplification mutation assay; TOB, tobramycin; UTI, urogenital tract infection;

177 WGS, whole-genome sequencing; WT, wild-type

178 *Novel multilocus sequence type (ST) identified in this study

179 #SCHI0032.S.32 submitted to PubMLST under isolate name AUS205 (ID:1023) (30)

180 ^SCHI0032.S.33 submitted to PubMLST under the isolate name AUS134 (ID:952) (30)

181 **Table 2. *Pseudomonas aeruginosa* isolates used for *gyrA*248 and *gyrA*259 SYBR-MAMA assay**

182 **validation, and associated fluoroquinolone-class antibiotic disc diffusion data**

gyrA phenotype	Isolate ID	CIP	LEV	OFX	MFX	WT to AMR (codon change)
AMR (mutant)	SCHI0003.S.3	I	I	R	R	*gyrA*248 T→C (T83I)
	SCHI0008.S.4	I	I	R	R	
	SCHI0010.S.1	R	R	R	R	
	SCHI0025.S.9	I	R	R	R	
	SCHI0016.S.124	R	R	R	R	*gyrA*259 G→A (D87N)
	SCHI0032.S.32	R	R	R	R	
	SCHI0003.S.8	I	I	R	R	*gyrA*259 G→C (D87H)
	SCHI0005.S.10	I	I	I	R	
	SCHI0025.S.15	R	R	R	R	
	SCHI0029.S.1	R	R	R	R	
	SCHI0032.S.33	R	I	R	R	*gyrA*259 G→T (D87Y)
WT (control)	SCHI0038.S.3	S	S	S	S	No mutation at *gyrA*248 or *gyrA*259
	SCHI0039.S.1	S	S	S	S	
	SCHI0050.S.1	S	S	S	S	
	PAO1	S	S	S	S	

183 Abbreviations: AMR, antimicrobial-resistant; CIP, ciprofloxacin; I, intermediate; LEV, levofloxacin;

184 MFX, moxifloxacin; OFX, ofloxacin; R, resistant; S, sensitive; WT, wild-type.

185 **Table 3. SYBR Green-based mismatch amplification mutation assay (SYBR-MAMA) primers**

186 **designed in this study**

***gyrA* SNP**	GyrA AMR variant	Primer name	Sequence (5'-3')*	Optimised concentration (µM)
***gyrA*248**	T83I	gyrA248_T_AMR	ACGATGGTGTCGTAGACCG<u>t</u>G**a**	0.30
		gyrA248_C_WT	CGATGGTGTCGTAGACCG<u>t</u>G**g**	0.30
		gyrA248_F	TGTGGTCGGCGACGTGATC	0.20
***gyrA*259**	D87N, D87Y, D87H	gyrA259_D_AMR	CATGCGCACGATGGTG<u>a</u>**d**	0.20
		gyrA259_G_WT	GCCATaCGCACGATGGTG<u>a</u>**c**	0.20
		gyrA259_F	AGCTGGGCAACGACTGGAA	0.20

187 Abbreviations: AMR, antimicrobial resistant (allele); SNP, single-nucleotide polymorphism; WT, wild-

188 type (allele)

189 *Bolded nucleotides indicate the SNP; underlined nucleotides indicate deliberately incorporated

190 antepenultimate/penultimate mismatches to enhance allele specificity

191 **Figures**



192

193 **Figure 1.** SYBR Green-based mismatch amplification mutation assay (SYBR-MAMA) interrogation of
194 the *gyrA*248 (T→C) biallelic single-nucleotide polymorphism, resulting in a threonine to isoleucine
195 substitution at position 83 (T83I) in certain fluoroquinolone (FQ)-resistant *P. aeruginosa* isolates.
196 *gyrA*248 SYBR-MAMA performance in: **A**. SCHI0010.S.1 (FQ-resistant, encodes T83I); **B.** SCHI0038.S.3
197 (FQ-sensitive wild-type isolate). Orange, antimicrobial-resistant allele; blue, wild-type allele. No-
198 template controls did not amplify. All samples were run in duplicate.



Figure 2. SYBR Green-based mismatch amplification mutation assay (SYBR-MAMA) interrogation of the *gyrA*259 (G→A/C/T) tetra-allelic single-nucleotide polymorphism, resulting in aspartate to asparagine (D87N), histidine (D87H), or tyrosine (D87Y) substitutions, respectively, at position 87 in certain fluoroquinolone (FQ)-resistant *Pseudomonas aeruginosa* isolates. *gyrA*259 SYBR-MAMA performance in: **A.** SCHI0005.S.10 (intermediate resistance towards FQs, encodes D87H); **B.** SCHI0032.S.32 (FQ-resistant, encodes D87N); **C.** SCHI0032.S.33 (FQ-resistant, encodes D87Y); and **D.** SCHI0038.S.3 (FQ-sensitive wild-type isolate). Purple, antimicrobial-resistant allele; aqua, wild-type allele. No-template controls did not amplify. All samples were run in duplicate.

208 **References**

209 1. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. 2011. *Pseudomonas aeruginosa*: all
210 roads lead to resistance. *Trends Microbiol* 19:419-26.
211 2. Botelho J, Grosso F, Peixe L. 2019. Antibiotic resistance in *Pseudomonas aeruginosa* -
212 Mechanisms, epidemiology and evolution. *Drug Resist Updat* 44:100640.
213 3. Schwartz T, Volkmann H, Kirchen S, Kohnen W, Schon-Holz K, Jansen B, Obst U. 2006. Real-
214 time PCR detection of *Pseudomonas aeruginosa* in clinical and municipal wastewater and
215 genotyping of the ciprofloxacin-resistant isolates. *FEMS Microbiol Ecol* 57:158-67.
216 4. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. 2003. Mutations in GyrA, ParC, MexR
217 and NfxB in clinical isolates of *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 21:409-13.
218 5. Poole K. 2011. *Pseudomonas aeruginosa*: resistance to the max. *Front Microbiol* 2:65-65.
219 6. Lee JK, Lee YS, Park YK, Kim BS. 2005. Alterations in the GyrA and GyrB subunits of
220 topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-
221 resistant clinical isolates of *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 25:290-5.
222 7. Yonezawa M, Takahata M, Matsubara N, Watanabe Y, Narita H. 1995. DNA gyrase *gyrA*
223 mutations in quinolone-resistant clinical isolates of *Pseudomonas aeruginosa*. *Antimicrob*
224 *Agents Chemother* 39:1970-1972.
225 8. Rehman A, Jeukens J, Levesque RC, Lamont IL. 2021. Gene-gene interactions dictate
226 ciprofloxacin resistance in *Pseudomonas aeruginosa* and facilitate prediction of resistance
227 phenotype from genome sequence data. *Antimicrob Agents Chemother* 65:e0269620.
228 9. Nguyen KV, Nguyen TV, Nguyen HTT, Le DV. 2018. Mutations in the gyrA, parC, and mexR
229 genes provide functional insights into the fluoroquinolone-resistant Pseudomonas
230 aeruginosa isolated in Vietnam. *Infect Drug Resist* 11:275-282.
231 10. Rehman A, Patrick WM, Lamont IL. 2019. Mechanisms of ciprofloxacin resistance in
232 *Pseudomonas aeruginosa*: new approaches to an old problem. *J Med Microbiol* 68:1-10.
233 11. Birdsell DN, Pearson T, Price EP, Hornstra HM, Nera RD, Stone N, Gruendike J, Kaufman EL,
234 Pettus AH, Hurbon AN, Buchhagen JL, Harms NJ, Chanturia G, Gyuranecz M, Wagner DM,
235 Keim PS. 2012. Melt analysis of mismatch amplification mutation assays (Melt-MAMA): a
236 functional study of a cost-effective SNP genotyping assay in bacterial models. *PLoS One*
237 7:e32866.
238 12. Germer S, Higuchi R. 1999. Single-tube genotyping without oligonucleotide probes. *Genome*
239 *Res* 9:72-8.
240 13. Donà V, Smid JH, Kasraian S, Egli-Gany D, Dost F, Imeri F, Unemo M, Low N, Endimiani A.
241 2018. Mismatch amplification mutation assay-based real-time PCR for rapid detection of
242 *Neisseria gonorrhoeae* and antimicrobial resistance determinants in clinical specimens. *J Clin*
243 *Microbiol* 56:e00365-18.
244 14. Sarovich DS, Price EP, Von Schulze AT, Cook JM, Mayo M, Watson LM, Richardson L,
245 Seymour ML, Tuanyok A, Engelthaler DM, Pearson T, Peacock SJ, Currie BJ, Keim P, Wagner
246 DM. 2012. Characterization of ceftazidime resistance mechanisms in clinical isolates of
247 *Burkholderia pseudomallei* from Australia. *PLoS One* 7:e30789.
248 15. Germer S, Holland MJ, Higuchi R. 2000. High-throughput SNP allele-frequency determination
249 in pooled DNA samples by kinetic PCR. *Genome Res* 10:258-66.
250 16. Webb KA, Olagoke O, Baird T, Neill J, Pham A, Wells TJ, Ramsay KA, Bell SC, Sarovich DS,
251 Price EP. 2021. Genomic diversity and antimicrobial resistance of *Prevotella* spp. isolated
252 from chronic lung disease airways. *MedRxiv*
253 doi:https://doi.org/10.1101/2021.08.30.21262864.
254 17. McCarthy KL, Paterson DL. 2017. Long-term mortality following *Pseudomonas aeruginosa*
255 bloodstream infection. *J Hosp Infect* 95:292-299.
256 18. Freschi L, Jeukens J, Kukavica-Ibrulj I, Boyle B, Dupont MJ, Laroche J, Larose S, Maaroufi H,
257 Fothergill JL, Moore M, Winsor GL, Aaron SD, Barbeau J, Bell SC, Burns JL, Camara M, Cantin
258 A, Charette SJ, Dewar K, Deziel E, Grimwood K, Hancock RE, Harrison JJ, Heeb S, Jelsbak L, Jia

259 B, Kenna DT, Kidd TJ, Klockgether J, Lam JS, Lamont IL, Lewenza S, Loman N, Malouin F,
260 Manos J, McArthur AG, McKeown J, Milot J, Naghra H, Nguyen D, Pereira SK, Perron GG,
261 Pirnay JP, Rainey PB, Rousseau S, Santos PM, Stephenson A, Taylor V, Turton JF, Waglechner
262 N, et al. 2015. Clinical utilization of genomics data produced by the international
263 *Pseudomonas aeruginosa* consortium. *Front Microbiol* 6:1036.
264 19. Stewart AG, Price EP, Schabacker K, Birikmen M, Harris PNA, Choong K, Subedi S, Sarovich
265 DS. 2021. Molecular epidemiology of third-generation-cephalosporin-resistant
266 Enterobacteriaceae in Southeast Queensland, Australia. *Antimicrob Agents Chemother*
267 65:e00130-21.
268 20. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP. 2009.
269 Identification of *Pseudomonas aeruginosa* by a duplex real-time polymerase chain reaction
270 assay targeting the *ecfX* and the *gyrB* genes. *Diagn Microbiol Infect Dis* 63:127-131.
271 21. Price EP, Viberg LT, Kidd TJ, Bell SC, Currie BJ, Sarovich DS. 2018. Transcriptomic analysis of
272 longitudinal *Burkholderia pseudomallei* infecting the cystic fibrosis lung. *Microb Genom*
273 4:e000194.
274 22. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI,
275 Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner
276 PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell
277 sequencing. *J Comput Biol* 19:455-477.
278 23. Madden DE, Webb JR, Steinig EJ, Currie BJ, Price EP, Sarovich DS. 2021. Taking the next-gen
279 step: comprehensive antimicrobial resistance detection from *Burkholderia pseudomallei*.
280 *EBioMedicine* 63:103152.
281 24. de Lamballerie X, Zandotti C, Vignoli C, Bollet C, de Micco P. 1992. A one-step microbial DNA
282 extraction method using "Chelex 100" suitable for gene amplification. *Res Microbiol*
283 143:785-90.
284 25. Fraser TA, Bell MG, Harris PNA, Bell SC, Bergh H, Nguyen T-K, Kidd TJ, Nimmo GR, Sarovich
285 DS, Price EP. 2019. Quantitative real-time PCR assay for the rapid identification of the
286 intrinsically multidrug-resistant bacterial pathogen *Stenotrophomonas maltophilia*. *Microb*
287 *Genom* 5:e000307.
288 26. Farahi RM, Ali AA, Gharavi S. 2018. Characterization of *gyrA* and *parC* mutations in
289 ciprofloxacin-resistant *Pseudomonas aeruginosa* isolates from Tehran hospitals in Iran. *Iran J*
290 *Microbiol* 10:242-249.
291 27. Takenouchi T, Sakagawa E, Sugawara M. 1999. Detection of *gyrA* mutations among 335
292 *Pseudomonas aeruginosa* strains isolated in Japan and their susceptibilities to
293 fluoroquinolones. *Antimicrob Agents Chemother* 43:406-409.
294 28. Akasaka T, Tanaka M, Yamaguchi A, Sato K. 2001. Type II topoisomerase mutations in
295 fluoroquinolone-resistant clinical strains of *Pseudomonas aeruginosa* isolated in 1998 and
296 1999: role of target enzyme in mechanism of fluoroquinolone resistance. *Antimicrob Agents*
297 *Chemother* 45:2263-2268.
298 29. Bergkessel M, Guthrie C. 2013. Colony PCR. *Methods Enzymol* 529:299-309.
299 30. Kidd TJ, Ritchie SR, Ramsay KA, Grimwood K, Bell SC, Rainey PB. 2012. *Pseudomonas*
300 *aeruginosa* exhibits frequent recombination, but only a limited association between
301 genotype and ecological setting. *PLoS One* 7:e44199.

302